Celon Pharma S.A.
I · AI Analysis
The brief
Celon Pharma develops and sells specialised generic drugs that treat serious conditions including cancers, neurological diseases, diabetes, and other metabolic disorders [Yahoo Finance]. As an integrated pharmaceutical company, they handle the full chain from research and development through manufacturing to marketing [Yahoo Finance].
Celon Pharma is a Polish integrated pharmaceutical company that researches, manufactures, and markets specialised generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders [Yahoo Finance]. Founded in 2002 and based in Lomianki, Poland, the company operates as a subsidiary of Glatton Sp. z o.o. and employs 560 people [Yahoo Finance]. The five analysts covering the company average an 'underperform' rating, with a mean 12-month price target of PLN 20.38 [Analyst consensus].
The company carries moderate concerns with negative operating margin, negative free cash flow, and a forward P/E suggesting analysts expect earnings to fall [Sentinellis calculation].
Sentinellis health
Moderate concerns
5.3/10
7.5+ strong · 4.5–7.5 moderate · under 4.5 weak
Profitability
Returns on capital
Growth & momentum
Balance sheet
Cash generation
Value creation
Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.
Market capitalisation
PLN 1.0B
Revenue (TTM)
PLN 257.6M
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadPremium · Free with any account
Operating margin is negative at -4.1%, meaning the company's core pharmaceutical business is currently unprofitable before non-operating items [Yahoo Finance].
Risks
8
Opportunities
5
Red flags
2
Leadership
2
14 more findings in the full report — free with any account.
Unlock the full Celon Pharma S.A. analysis
Create a free account to access the complete AI-generated report with inline citations.
- 8 risks, 5 opportunities and 2 red flags — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?